News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines, Says Frost & Sullivan
6/20/2013 8:44:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LONDON – 20 June 2013 – Molecular farming is poised to address the huge demand for fully functional protein therapeutics and low-cost vaccines. This plant production technology is deployable for applications in basic life sciences research, veterinary applications, personal care, and healthcare to meet the clinical needs of chronic and orphan diseases unmet by the current supply.
New analysis from Frost & Sullivan’s (HYPERLINK "http://www.frost.com/prod/servlet/ti-home.pag"http://www.technicalinsights.frost.com) Emerging Trends in Molecular Farming research finds plants are preferred production systems owing to their potential to produce a wide range of recombinant molecules. Post-translational modifications in plants allow for their use in the production of complex proteins, giving them an edge over conventional bacterial systems.
For more information on this research, please email Anna Zanchi, Corporate Communications, at firstname.lastname@example.org
“Plant farming offers a cost-effective platform for recombinant protein production, especially as setting up a plant-based platform requires low costs and provides flexibility,” says a Technical Insights analyst. “These benefits prompted research on novel plant-based platforms, process design and optimization, and will lead to the development of sustainable and scalable production systems.”
However, stringent regulations, possible safety issues and the lack of participation from stakeholders pose a challenge to technology development and adoption. Recombinant proteins’ post-translational modifications and minor glycosylation differences from human proteins may lead to a loss in functions or immune reactions, and can reduce drug performance and safety.
These barriers have compelled several researchers to work on glycosylation modified plants to create suitable, humanized glycoengineered therapeutic proteins. In addition, researchers must focus on improving downstream processing methods to significantly shrink overall costs associated, and develop targeting strategies for protein secretion in the culture medium.
"Techniques such as strong promoters and fusion protein expression can be used to improve expression levels,” notes the analyst. “Core expression technology developers must also leverage DNA transfection, the development of gene knockout plants and similar bioprocess techniques to build proteins with enhanced therapeutic and economic value.”
Though molecular farming is not fully mature, the technology will gain momentum through collaborations and licensing deals.
Emerging Trends in Molecular Farming, part of the Technical Insights subscription, provides the research portfolio of various molecular farming technologies and platforms, research orientation based on applications, key technical and industry challenges for molecular farming initiatives and research, key drivers, market needs from plant production systems and R&D focus areas for researchers and companies, and recent partnerships and alliances. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters and research services.
Connect with Frost & Sullivan on social media, including our Healthcare group on LinkedIn, for the latest news and updates.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Corporate Communications – Europe
P: 0039 02 48516133
Help employers find you! Check out all the jobs and post your resume.